EP1534666A1

EP1534666A1 - Compounds for modulating the glycolosis enzyme complex and/or transaminase complex

Info

Publication number: EP1534666A1
Application number: EP03794769A
Authority: EP
Inventors: Erich Eigenbrodt; Hans Scheefers; Sybille Mazurek
Original assignee: ScheBo Biotech AG
Current assignee: ScheBo Biotech AG
Priority date: 2002-09-06
Filing date: 2003-07-07
Publication date: 2005-06-01
Also published as: US7223784B2; JP2005538165A; US20040147587A1; AU2003258454A1; CA2498045A1; WO2004024676A1; US20070238781A1

Abstract

The invention relates to compounds for modulating the glycolysis enzyme complex and transaminase complex, pharmaceutical compositions containing such compounds and the uses of said compounds in the production of pharmaceutical compositions for the treatment of various diseases.

Description

Compounds for modulating the glycolysis-enzyme and / or transaminase complex.

Field of the Invention.

The invention relates to compounds for modulating the glycolysis-enzyme and / or transaminase complex and consequently in particular to inhibiting the growth of cells and / or bacteria, pharmaceutical compositions containing such compounds and uses of such compounds for the production of pharmaceutical compositions for the treatment of various diseases.

Background of the Invention.

Cancer is one of the leading causes of death these days and the number of cancer cases in industrialized countries is constantly increasing. This is mainly due to the fact that malignant tumors are a disease of old age and, thanks to the successful fight against infectious diseases, more people are reaching this age. Despite all the advances in the diagnostic and therapeutic fields, the prospects for a cure for the most common forms of internal cancer are rarely over 20%. A cancerous growth can currently be destroyed or inhibited in its growth. A regression of a tumor cell into a normal cell cannot yet be achieved. The main therapeutic measures, surgery and radiation, remove cancer cells from the organism. Also the currently used Che otherapeutika des Cancer, the cytostatics, only lead to the destruction or damage of tumor cells. The effect is so little specific in most cases that severe damage to healthy cells occurs at the same time.

In general, tumor cells have a metabolism that differs from that of healthy cells, in particular glycolysis. For example, a change in the isoenzyme system involved in glycolysis and a change in the transport of NADH is typical for tumor cells. Et al the activity of the enzymes of glycolysis is increased. This also allows high sales under the aerobic conditions typical of tumor cells. In detail, E. Eigenbrodt et al. , Biochemical an Molecular Aspects of Selected Cancers, Vol. 2, pp. 311 ff., 1994.

Various other diseases mentioned below either go hand in hand with (excessive) metabolism via the glycolysis-enzyme complex and can be treated by reducing or inhibiting it.

State of the art.

From the literature reference E. Eigenbrodt et al. , Biochemical on Molecular Aspects of Selected Cancers, Vol. 2, p. 311 ff., 1994, it is known to use glucose analogs to inhibit glycolysis. Other approaches known from this are the use of inhibitors of glycolytic isoenzymes, for example by suitable complex formation or inhibition of complex formations. As a result, tumor cells are starved. The problem with the above compounds is that many of them are genotoxic and / or not sufficiently specific for tumor cells.

Technical problem of the invention.

The present invention is based on the technical problem of specifying active substances which are able to modulate or inhibit the glycolysis-enzyme and transaminase complex, in particular the proliferation of

To inhibit cancer cells and thus the growth of neoplastic tumors as well as excessive defense reactions of the body, e.g. to inhibit septic shock, autoimmune diseases, graft rejection and acute and chronic inflammatory reactions, with at the same time only little to no cytotoxicity towards cells with intact glycolysis-enzyme complex or other complex structures. In addition, the growth of unicellular organisms is said to be inhibited.

Basics of the invention.

To solve this technical problem, the invention teaches a compound according to formula I.

where Rl = -CN, -COO +, -COS +, -COOH, -COSH, -COOR1.1, -COSR1.1, where Rl .1 = -H, Cl-10 alkyl, Cl-10 aralkyl and aryl, respectively R2 = -H, -OR1.1, -Hai (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am, where R3 = -H , -OR1.1, -Hai (-F -Cl, -Br, -J), -NR2.1R2.2, -Am, -O-Am, -S-Am, where R2.1 = -H, Cl -10 alkyl, Cl-10 aralkyl or aryl, where R2.2 = -H, Cl-10 alkyl, Cl-10 aralkyl or aryl, where R2.1 and R2.2 can be identical or different, where n and m may be the same or different and 0 to 10, where o and p may be the same or different and 0 to 3, where o> 0 if n and m = 0, where R2 and R3 are the same or different for Cn and Cm where R2 can be the same or different for each Cx = 1 ... n, where R3 can be the same or different for each Cy = 1 ... m, where -Am represents an amino acid residue, where q and r = 0 or 1 and are identical or different, where -O _r - and / or -O _q - can also be replaced by -S _r - or -S -, where - NR2.1R2.2 can be replaced by linear or branched -C1-C20 alkyl, or a physiologically acceptable salt of such a compound.

An amino acid residue is defined in an amino acid as follows: NH ₂ -CHAm-COOH. Amino acid residues of the proteinogenic amino acids, especially the essential amino acids, are particularly suitable. Insofar as a connection according to the invention has optical activity (for example in accordance with embodiments of claim 3), the various variants, such as L and D forms, are also included. The same applies in the case of (several) chiral centers.

Compounds according to the invention are particularly suitable, where R2 is at least simply present as -Am, where -Am is preferably an essential amino acid residue Represents amino acid, in particular q = 0 and r = 1 or q = 1 and r = 0 or q = 1 and r = 1, m = 1, R3 = -H, n = o = p = 0, R2.1 = R2.2 = -H is.

Furthermore, various specific groups are preferred, namely: i) where n = o = p = 0, where m = 0 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = -H , where q = 0 and r = 1, ii) where m = p = 0, where o = 1, where n = 0 to 4, where R2 = H, where R3 = -H or -Hai im Case of Cx = 1, where R3 = -H for all Cx = n> 1, where R2.1 = R2.2 = -H, where q = 0 and r = 1, iii) where m = 1 to 4, where n = o = p = 0, where R2 = H, where R3 = -H or -Hai in the case of Cy = 1, where R3 = -H is for all Cy = m> l, where R2.1 = R2.2 = -H, where q = 0 and r = 1, iv), where o = p = 1, where m = 0, where n = 0 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = -H, where q = 0 and r = 1, v), where n = p = 0, where 0 = 1, where m = Is 0 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = -H, where q = 0 and r = 1, or vi) where m = p = 0, where o = 1, where n = 1 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = -H, where q = 0 and r = 1.

In general, an R2 can be replaced by -Am.

Examples of compounds in which -NR2.1R2.2 is replaced by -C1-C20 alkyl are: CH ₃ -0- (CH ₂ ) _m -Rl, CH ₃ -O-CO- (CH ₂ ) _m -Rl, CR5R6R7-0- (CH ₂ ) _m -Rl, CR5R6R7-0-CO- (CH ₂ ) _m -Rl, where R5, R6 and R7 -C1-C10 can be alkyl, linear or branched, unsubstituted or substituted. (CH ₂ ) can of course also be (CR2R3). -O- or = 0 can be replaced by -S- or = S his. Rl is as indicated above. CR5R6R7 can in particular be t-butyl.

Examples of compounds according to the invention are: NH ₂ -0- (CH2) _m -Rl, NH, -0- (CH ₂ ) _n -CO-Rl, NH ₂ -0-CHHal- (CO) ₀ -Rl, NH ₂ - 0-CHHal-CH ₂ - (CO) _D -R1, NH ₂ -0-CHHal- (CH ₂ ) ₂ - (CO) ₀ -Rl, NH ₂ -0-CHHal- (CH ₂ ) ₃ - (C0) _o -Rl, NH ₂ -0-CHHal- (CH ₂ ) ₄ - (C0) _o -Rl, NH ₂ -0-CO- (CH ₂ ) _n -CO-Rl, H ₂ -C ~ CO- (CH ₂ ) _n -Rl, NH ₂ -0- (CH ₂ ) _n -C0-Rl, NH ₂ -0-CO- (CH ₂ ) _n -CHNH ₂ -Rl, NH ₂ -0- (CH ₂ ) _n - CHNH ₂ -Rl, with Rl = -CN or -COOH, m or n = 0-4, o = 0 or 1, where -0- can be replaced by S.

Another formula according to the invention is formula II

where R _a = -CN, R _b = -H, = 0, -OH, -NH ₂ , R _c = - H ₂ , -0-NH ₂ , -0- (Cl-10) alkyl, R _d = - H, -Hai, = 0, -OH, where in the case of = 0 the H of a CH is omitted, where w = 0-10, for example 1 to 4.

Another formula according to the invention is formula III

Rp Rq

\ s

III c

Rr Rs

where Rp = -Rl, -0-Rl, -0- (CR2R3) _χ -Rl, - (CR2R3) „-0-R1, Rq

-NR2.1R2.2, -0-NR2.1R2.2, -0- (CR2R3) _χ -NR2.1R2.2,

- (CR2R3) _χ -0-NR2.1R2.2, Rr = -Am, -O-Am, -0- (CR2R3) _χ -Am, - (CR2R3) _χ -0-Am, Rs = -H, -C1-C10 alkyl, aryl or araklyl, -C1-C10 hydroxyalkyl, aryl or aralkyl, or an ether of such a hydroxyl radical, where -0- can be replaced by -S- and x = 1 to 10, in particular 1 to 4. Rl is as stated above, in particular -CN or -COOH, examples of such compounds are: NH ₂ -0-CHAm-Rl, NH ₂ -CHAm-0-Rl , NH ₂ -0-CHAm-0-Rl, NH ₂ -CHRl-0-Am, Äm-0-CHNH ₂ -0-Rl, NH ₂ -0- (Am-O-CH-O-Rl). On one side of a -0- or more -0- or on both sides of a -0- or more -0- there can be an immediate - (CH ₂ ) _X - interposed.

Substances according to the invention can, depending on the pH, be ionized in solution (for example as -C00 ^" in basic or as -NH ₃ ⁺ in acid). Salts such as hydrochlorides etc. can also be formed.

The invention is based on the knowledge that in addition to classic metabolic diseases such as diabetes mellitus, obesity, other diseases such as cancer, autoimmune diseases and rheumatism are also caused by metabolic derangements. This explains the strong influence of diet on these diseases. A direct measurable biochemical parameter for these metabolic derailments is the increase in pyruvate kinase type M2 (M2-PK), which increases in the blood of patients with all of the diseases mentioned above and below. Depending on the respective disease, the M2-PK detectable in the patient's blood comes from different cells: in cancer from tumor cells, in sepsis from immune cells, in rheumatism from immune and / or sinovial cells. In healthy cells, the tetrameric form of M2-PK is found in a highly ordered cytosolic complex, the glycolysis Enzyme complex. The overactivation of oncoproteins leads to the migration of M2-PK from the complex and the typical changes in tumor metabolism. At the same time, the phosphoglyceromutase (PGM) leaves the complex and migrates to another enzyme complex in which cytosolic transaminases are associated (see Example 2). This complex is therefore called the transaminase complex. The substrate of the PGM, glycerate-3-P, is the precursor for the synthesis of the amino acids serine and gly- a. Both amino acids are essential for DNA and phoypholipid synthesis. Immigration of the PGM into the transaminase complex activates the synthesis of serine from glutamate and thus the glutaminolysis. The same changes take place in immune cells when the immune system derails, such as rheumatism, sepsis or polytrauma. The integration of the metabolism of different cells in multicellular organisms takes place through organ-specific association of the enzymes in the cytosol: in the muscle, for example, through association with contraction proteins. For this reason, the various organs are each equipped with specific isoenzymes. The dissolution of this order inevitably leads to illnesses. Unicellular organisms, such as bacteria or yeast, which react to sufficient food with unrestrained proliferation do not have a complex cytosol organization. Consequently, substances that inhibit the derailed metabolism of multicellular organisms also inhibit the proliferation of such unicellular organisms.

The invention further teaches the use of a compound according to the invention for the production of a pharmaceutical composition for the treatment of one or more diseases from the group consisting of "cancer, chronic inflammation, asthma, arthritis, osteoarthritis, chronic polyarthritis, rheumatic arthritis, inflammatory bowl disease, degenerative joint diseases, diseases of the rheumatic type with cartilage breakdown, sepsis, autoimmune diseases, type I diabetes, hashimotoid thyroiditis, autoimmune thrombitis, autoimmune thrombocytopenia "Inflammatory bowel diseases, Crohn's disease, uveitis, psoriasis, collagenosis, Goodpasture syndrome, diseases with impaired leukocyte adhesion, cachexia, diseases due to increased TNFalpha concentration, diabetes, obesity, bacterial infections, especially with resistant bacteria". The term treatment also includes prophylaxis.

The invention further teaches a pharmaceutical composition, wherein a compound according to the invention is mixed with one or more physiologically compatible adjuvants and / or carriers and galenically for local or systemic administration, in particular orally, parenterally, for infusion or infusion into a target organ, for injection ( egi., im, intracapsular or intralumbal), is prepared for application in tooth pockets (space between the tooth root and gums).

Finally, the invention teaches the use of a compound according to the invention for in vitro inhibition of the glycolysis-enzyme complex, in particular pyruvate kinase, asparaginase, serine dehydratases, transaminases, desaminases, and / or glutaminases. In particular, transamination, oxidative deamination, hydrolytic deamination, and eliminating are blocked Deamination and reductive deamination.

It is understood that various stereoisomers may exist for compounds of the formula I, all of which are the subject of the invention. The term alkyl includes linear and branched alkyl groups and cycloalkyl, optionally also cycloalkyl groups with linear or branched alkyl substituents. The term aryl also includes aralkyl groups, where alkyl substituents can be alkyl or cycloalkyl.

Surprisingly, it has been found that compounds according to the invention are able to inhibit the aforementioned members of the glycolysis-enzyme complex. The proliferation of cancer cells in therapeutically relevant concentrations can be inhibited. No cytotoxic effects are expected in the dose range in question. Because of their pharmacological properties, the compounds according to the invention are also outstandingly suitable for the treatment and prophylaxis of the other diseases listed above. In connection with the indications for anti-inflammatory or antirheumatic effects, it is particularly relevant that the substances according to the invention are non-steroidal substances.

The inhibition of the glycolysis-enzyme and the transaminase complex includes in particular the inhibition of

Metabolism and energy gain from serine, glutamine, ornithine, proline and arginine or from other amino acids of these or other families, however also the synthesis of such amino acids used for energy generation; important energy sources, for example in tumor cells, but also in bacteria and yeast. The cells or bacteria or yeast are starved, so to speak. Specifically, substances according to the invention block, for example, the following reactions: i) threonine to glycine, ii) threonine to α-amino-β-ketobutyrate, iii) -amino-β-ketobutyrate to glycine, iv) see serine pyridoxal phosphate (PLP) Schiff Base to aminoacrylate, in particular the folic acid-dependent serine hydroxymethyltransferase, v) aminoacrylate to pyruvate (by shifting the equilibrium of the natural hydrolysis of the PLP Schiff base to the Schiff base), vi) transamination by means of PLP to synthesize an amino acid an oxo acid, especially the branched chain transaminase, the α-ketoglutarate, oxaloacetate, 3-hydroxypyruvate and glyoxalate transaminase, the glutamate dehydrogenase. In particular, the formation of pyruvate occurs with substances according to the invention

Amino acids inhibited. It is important to release NH ₂ -OH or CH3-OH (-H at C or N, possibly replaced by other radicals, for example alkyl) by glutaminase, arginase, asparaginase or serine hydroxymethyltransferase. This leads to an increased specificity, since a characteristic of tumor cells is a high glutaminase and serine hydroxymethyltransferase activity. NH ₂ -OH (hydroxylamine, HA), for example, can be phosphorylated by the high pyruvate kinase activities instead of the -OH of the phosphate (for example the ADP). This leads to the decoupling of the pyruvate kinase reaction in tumor cells. Therefore, in general, the invention also includes all natural metabolites of the Substances according to the invention, in particular of amino oxyacetate, ie fragments of these substances.

In addition to PGM and NDPK, the cytosolic isoforms of the glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), glutamate dehydrogenase (GIDH) and malate dehydrogenase (MDH) are associated in the transaminase complex. The 'GOT and MDH are components of the malate-aspartate shuttle, which transports the hydrogen produced in the cytosol to the mitochondria. NAD + is recycled for the cytosolic glyceraldehyde 3-phosphate dehydrogenase reaction. The malate-aspartate shuttle is part of glutaminolysis. For an active malate-aspartate shuttle, this is in addition to the GOT

Presence of the p36 bound form of MDH is important, as shown in Example 3.

Various other embodiments are possible within the scope of the invention. Thus, a pharmaceutical composition according to the invention can contain several different compounds falling under the above definitions. Furthermore, a pharmaceutical composition according to the invention can additionally contain an active ingredient different from the compound of the formula I. Then it is a combination product. The various active ingredients used can be prepared in a single dosage form, ie the active ingredients are mixed in the dosage form. However, it is also possible to prepare the different active substances in spatially separate dosage forms of the same or different types. Counter ions for ionic compounds according to formula I are Na ⁺ , K +, Li +, cyclohexylammmonium, or basic amino acids (eg lysine, argini, ornithine, glutamine).

The medicaments produced with the compounds according to the invention can be administered orally, intramuscularly, peri-articularly, intra-articularly, intravenously, intraperitoneally, subcutaneously or rectally.

The invention also relates to processes for the production of medicaments which are characterized in that at least one compound of the formula I is brought into a suitable dosage form with a pharmaceutically suitable and physiologically tolerable carrier and, if appropriate, other suitable active ingredients, additives or auxiliaries.

Suitable solid or liquid galenic

Forms of preparation are, for example, granules, powders, dragees, tablets, (micro) capsules, suppositories, syrups, juices, suspensions, emulsions, drops or injectable solutions, and preparations with a protracted active ingredient release, which are customary in their preparation

Auxiliaries such as carriers, explosives, binders, coating agents, swelling agents, lubricants or lubricants, flavorings, sweeteners and solubilizers are used.

Magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and their derivatives, animal and vegetable oils such as cod liver oil, sunflower, peanut or sesame oil, polyethylene glycols and solvents, such as sterile water and mono- or polyhydric alcohols, for example glycerol.

The medicaments are preferably produced and administered in dosage units, each unit containing as active ingredient a defined dose of the compound of the formula I according to the invention. In the case of solid dosage units such as tablets, capsules, coated tablets or suppositories, this dose can be 1 to 1000 mg, preferably 50 to 300 mg, and in the case of injection solutions in ampoule form 0.3 to 300 mg, preferably 10 to 100 mg.

For the treatment of an adult patient weighing 50 to 100 kg, for example 70 kg, daily doses of 20 to 1000 mg of active ingredient, preferably 100 to 500 mg, are indicated, for example. Under certain circumstances, however, higher or lower daily doses may also be appropriate. The daily dose can be administered either by single administration in the form of a single dosage unit or else several smaller dosage units, or by multiple administration of divided doses at certain intervals.

The invention is explained in more detail below on the basis of examples which merely illustrate embodiments.

Example 1: Quantification of the effectiveness of a compound according to the invention Novikoff hepatoma cells that can be used are available from the tumor bank of the German Cancer Research Center, Heidelberg, (Cancer Research 1951, 17, 1010). 100,000 cells are sown per 25 cm ² cultivation bottle. A substance according to the invention, dissolved in a solvent suitable for use in cell cultures such as water, dilute ethanol, dimethyl sulfoxide or the like, is added to the culture medium in increasing concentration, for example in the concentration range from 80 μm to 5000 μm or from 100 μm to 300 μm. After four days of cultivation, the number of cells per bottle is counted. In comparison to the control sample (without the addition of a compound according to the invention or with the alternative addition of a reference compound), one can see the extent and the dose dependency of an inhibition of proliferation of the compound used.

Example 2: Emigration of the PGM

FIG. 1 a shows an isoelectric focusing of a tumor cell extract (MCF-7 cells). It can be seen that PGM leaves the glycolysis-enzyme complex and migrates into a complex associated with the cytosolic transaminases, the transaminase complex. The transaminase complex is composed as follows: cytosolic

Glutamate oxaloacetate transaminase (GOT), c-malate dehydrogenase (MDH), phosphoglyceromutase (PGM). Not shown are: c-glutamate pyruvate transaminase (GPT), c-glutamate hydroxypyruvate transaminase, c-alanine hydroxypyruvate transaminase, c-serine hydroxymethyl transferase and c-glutamate dehydrogenase (GIDH). The PGM and the nucleotide diphosphate kinase (NDPK) can be used in both Transaminase- as well as be associated in the glycolysis-enzyme complex.

Example 3: Inhibition of the malate-aspartate shuttle

FIG. 1b shows the effect of aminooxyacetate (AOA) and hydroxylamine (HA) on the activity of the cytosolic and mitochondrial isoenzyme of the GOT in vitro. The GOT isoenzymes were separated by isoelectric focusing. It can be seen that aminooxyacetate, in particular the cytosolic isoenzyme and hydroxylamine, inhibit both GOT isoenzymes. The inhibition of the GOT leads to an inhibition of the malate-aspartate shuttle. As a result, NAD cannot be recycled and glycolysis is inhibited at the GAPDH level.

The following statements are independent of the examples above. The invention further teaches the use of N- (4'-trifluoromethylphenyl) -5-methylisoxazole-4-carboxamide (C ₁₂ H ₉ F ₃ N ₂ 0 ₂ ; MW 270.2, see also FIG. 2a) and / or its natural one active metabolites A 77 1726 according to Figure 2b for the preparation of a pharmaceutical composition for the treatment of

Tumor diseases, especially solid tumors. As an alternative to the substitution shown with -CF3, the benzene ring can in general be substituted with -CHal3 or -0-CHal3 or -Hai at any point, once, twice, three times, four times or five times. The pharmaceutical composition according to the invention is particularly suitable for the treatment of large tumors, ie from 0.1 to 1 cm ³ tumor size. An inventive The pharmaceutical composition is prepared, for example, for oral administration, for example with the following auxiliaries and carriers: colloidal Si0 ₂ , crospovidone, hydroypropylmethyl cellulose, lactose monohydrate, magnesium stearate, polyethylene glycol, povidone, starch, talc, Ti0 ₂ , and / or yellow iron oxide. The dosage is 1 to 50 mg daily, preferably 10 to 30 mg. It may be advisable to initially administer a starting dose of 20 to 500 mg, in particular 50 to 150 mg, for the first 1 to 10 days, in particular the first 1 to 3 days. In a further embodiment of the invention, the substance mentioned at the outset is reacted with one or more sugar phosphates, for example fructose-1, 6-bisphosphate, glycerate-2, 3-bisphosphate, glycerate-3-phosphate, ribose-1, 5-bisphosphate, ribulose- 1, 5-bisphosphate, combined, the combination of substances can be mixed in a dosage form, for example tablets. However, it is also possible to provide the components separately in the same or different administration forms. The

Sugar phosphate can be administered in a dosage of 20 to 5000 mg per day, for example 100 to 500 mg.

These variants of the invention surprisingly lead to the inhibition of the growth of tumor cells and tumor tissue, because these substances or the metabolite bind to the pyruvate kinase and can inhibit or reverse the energy metabolism derailed for tumor cells. From these relationships there is a particular advantage that these substances are specific in the metabolism of tumor cells and not or less in those of Normal cells intervene and there may be little side effects.

The effectiveness of these substances is surprising because the known effect as a pyrimidine synthesis inhibitor affects a completely different mechanism of action and the phenomenological observation of an antiproliferative effect is essentially directed at immune cells and cells which are connected with inflammatory diseases.

Of particular importance is also a combination of one or more of the active ingredients mentioned on the previous page with one or more of the previous active ingredients or aminooxyacetate (AOA,

NH2-0-CH2-COOH, salts or esters, for example Cl-CIO alkyl or hydroxyalkyl esters, of these). For example, AOA is particularly effective on small tumors (<0.1 to 1 cm ³ ) or prevents their formation, in particular the formation of metastases, while compounds of the formulas 10 or 11, if appropriate in combination with sugar phosphate, are effective against the large tumors , The reason for this is the different metabolism in small and large tumors. The above statements on combinations apply analogously.

Substances according to the invention can furthermore be used for producing a pharmaceutical composition for the treatment of heart failure or chronic cardiac failure (CCF). This includes the variants or grades from NYHA I to NYHA IV defined in the New York Heart Association (NYHA) Classification. All of these diseases are acute and / or chronic inability of the heart muscle, under stress or to bring up the blood expectoration or the necessary support necessary for the metabolism of the organism in peace. The reasons for this lie in the insufficient glycolysis due to a lack of glucose in the heart muscle and / or its insufficient oxygen supply as well as in complex coronary inflammatory processes (activation of cells of the immune system and complement). This aspect of the invention is based on the knowledge that alternative energy-generating biochemical processes are modulated with the substances according to the invention and thus it is also possible, as it were, to create replacement paths for the above-mentioned poorly functioning processes, for example by activating the serolysis or Glutaminolysis or with substances according to the invention to shift the existing dynamic balance between glycolysis on the one hand and glutaminolysis on the other hand in favor of glycolysis with simultaneous administration of oxygen (increase in the oxygen partial pressure in the blood, for example by ventilation). In this context, the administration of anti-inflammatory substances according to the invention, the threatening life-threatening acidosis (due to lactate formation) can be avoided. Compared to the known measures, such as administration of ACE inhibitors, diuretics, digitalis, positively inotropic substances, or isosorbide dinitrate, the substances according to the invention intervene directly in the energy metabolism and improve it. As a result, side effects are comparatively minor.

In this connection, it was also found in the context of the invention that, at least in the cases of NYHA Grade II to IV, the concentration of tumor M2-PK (= M2-PK dimer in contrast to normal M2-PK, which is present tetramer) in Cells and / or blood increases, which can be determined routinely easily, in contrast to previously common methods. The invention therefore furthermore teaches the use of a test system which detects tumor M2-PK for producing a diagnostic agent for in vitro diagnosis of heart failure, in particular also of the degree or the associated inflammatory processes. If, in a patient in blood plasma, compared to standard values (defined maximum limit values; normal collective), increased tumor M2-PK values (collective of the sick) are found, this is indicative of the presence of heart failure and / or of inflammation processes correlated with it, or at least of the risk to develop heart failure. Such a blood plasma analysis can be carried out easily and at short notice. In contrast, previous standard methods (gold standard, blood gas analysis) are unsuitable for routine use and expensive. In the context of this aspect of the invention, any known test systems can be used which detect tumor M2-PK, for example immunological test systems with antibodies. In particular, test systems known per se can also be used which detect tumor M2-PK as tumor metabolism markers, for example monoclonal antibodies specific therefor.

Various substances that can be used according to the invention are shown in the further figures. In particular, the essential possible variations are shown by way of example, the permutations which are readily apparent therefrom not shown for the sake of simplicity. Finally, the invention also includes all natural metabolites of the substances described

Claims

Claims:

1. Compound according to formula I.

where Rl = -H, -CN, -COO +, -COS +, -COOH, -COSH,

-COOR1.1, -COSR1.1, N-phthalimidyl where R1 = = H, Cl-10 alkyl, Cl-10 aralkyl or aryl, where R2 = -H, C1-C4 alkyl, -OR1.1, -Hai (-F -Cl, -Br,

-J), -NR2.1R2.2, -Am, -O-Am, -S-Am, where R3 = -H, C1-C4 alkyl, -OR1.1, -Hai (-F -Cl, -Br .

-J), -NR2.1R2.2, -Am, -O-Am, -S-Am, where R2.1 = -H, Cl-10 alkyl, Cl-10 aralkyl or aryl, where R2.2 = -H, Cl-10 alkyl, Cl-10 aralkyl or aryl, where R2.1 and R2.2 may be the same or different, where n and m may be the same or different and 0 to 10, where o and p are the same or can be different and can be 0 to 3, where o> 0 if n and m = 0, where R2 and R3 can be the same or different for Cn and / or Cm, where R2 is the same for each Cx = 1 ... n or can be different, where R3 can be the same or different for each Cy = 1 ... m, where -Am represents an amino acid residue, where q and r = 0 or 1 and are the same or different, where -O _r - and / or -0 _q - can also be replaced by -S _r - or -S _q -, where -NR2.1R2.2 can be replaced by linear or branched -C1-C20 alkyl, aralkyl or Aryl, where a group -CN, - (CO) -CN, - (CO) -O-Rl or - (CO) -Rl or -CO-Rl can be replaced by -S0 ₂ -NR2.1R2.2, or a physiologically acceptable salt of such a compound.

2. A compound according to claim 1, wherein Rl = -CN.

3. A compound according to claim 1 or 2, wherein R2 is at least simply present as -Am, where -Am preferably represents an amino acid residue of an essential amino acid, in particular q = 0 and r = 1 or q = 1 and r = 0 or q = 1 and r = 1, m = 1, R3 = -H, n = o = p = 0, R2.1 = R2.2 = -H.

4. A compound according to claim 1 or 2, wherein n = o = p = 0, where m = 0 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = -H, where q = 0 and r = 1.

5. A compound according to claim 1 or 2, wherein m = p = 0, where o = 1, where n = 0 to 4, where R2 = H, where R3 = -H or -Hai in the case of Cx = l is, where R3 = -H for all Cx = n> l, where R2.1 = R2.2 = -H, where q = 0 and r = 1.

6. A compound according to claim 1 or 2, wherein m = 1 to 4, where n = o = p = 0, where R2 = H, where R3 = -H or -Hai in the case of Cy = 1, wherein R3 = -H is for all Cy = m> l, where R2.1 = R2.2 = -H, where q = 0 and r = 1.

7. A compound according to claim 1 or 2, wherein o = p = 1, where m = 0, where n = 0 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = - Is H, where q = 0 and r = 1.

8. A compound according to claim 1 or 2, wherein n = p = 0, where 0 = 1, where m = 0 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = - Is H, where q = 0 and r = 1.

9. A compound according to claim 1 or 2, wherein m = p = 0, where o = 1, where n = 1 to 4, where R2 = R3 = -H, where R2.1 = R2.2 = - Is H, where q = 0 and r = 1.

10. A compound according to any one of claims 4 to 9, wherein an R2 is replaced by -Am.

11. Use of a compound according to any one of claims 1 to 10 for the manufacture of a pharmaceutical composition for the treatment of one or more Diseases from the group consisting of "cancer, rheumatism, chronic inflammation, asthma, arthritis, osteoarthritis, chronic polyarthritis, rheumatic arthritis, inflammatory bowl disease, degenerative joint diseases, diseases of the rheumatic type with cartilage breakdown, sepsis, autoimmune diseases, type I diabetes, Hashimoto's thyroiditis, autoimmune thrombocytopenia, multiple sclerosis, myasthenia gravis, chronic inflammatory bowel diseases, Crohn's disease, uveitis, psoriasis, collagenosis, goodpasture syndrome, diseases with disturbed leukocyte adhesion, cachexia, concentration due to increased diabetes, adiposephalitis infections , especially with resistant bacteria (antibiotic) ".

12. Pharmaceutical composition, wherein a compound according to one of claims 1 to 10 is mixed with one or more physiologically compatible adjuvants and / or carriers and galenically prepared for local, in particular oral, or systemic, in particular IV administration.

13. Use of a compound according to any one of claims 1 to 10 for in vitro and / or in vivo inhibition of glycolysis and / or glutaminolysis, in particular pyruvate kinase, asparaginase, serine dehydratases, transaminases, glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, glutamate dehydrogenase, Malate dehydrogenase, deaminases, and / or glutaminases, especially in pro- and / or eukaryotes.